HOME > BUSINESS
BUSINESS
- JCR Bags FDA’s Orphan Tag for MPS IIIA Drug in US
December 15, 2023
- Shionogi Ships 1st Batch of Cough Drug Medicon after Ramp-Up
December 15, 2023
- Leqembi to Debut on Dec. 20; Eisai Sees SC Version and Blood Biomarker as Drivers for Wider Use
December 14, 2023
- Novo Nordisk Expects to Lift Restrictions on Ozempic Shipments in Early January
December 14, 2023
- Torii Scoops Up Japan Rights for Grass Pollinosis Med
December 14, 2023
- Avastin Biosimilars Add Malignant Glioma Indication in Japan
December 14, 2023
- Prograf Generics Now on Equal Footing with Original Product
December 14, 2023
- Mochida Intends to Carve Out Market Share with 1st G-Lasta Biosimilar
December 13, 2023
- GSK Seeks Label Expansion of Arexvy for High-Risk Adults Aged 50-59
December 13, 2023
- Total Sales of 26 Japan Drug Makers Up 6.1% in H1; Shionogi Nets Largest Growth
December 12, 2023
- Sobi Eyes Japan Approval of 4 Rare Disease Drugs in 5 Years: Local Chief
December 12, 2023
- Astellas’ Hot Flash Drug Bags European Nod
December 12, 2023
- Lenvima-Keytruda Combo Misses Goal in 1st Line Endometrial Cancer
December 12, 2023
- NEC Harnessing AI Prowess to Pursue Global Players in Cancer Vaccine Race
December 11, 2023
- KM, Meiji Initiate PIII Pediatric Trial for XBB.1.5-Adapted COVID Vaccine
December 8, 2023
- Pivlaz Approved in South Korea, Set for Launch in Early 2025
December 8, 2023
- Japan Ethical Drug Sales Up 8.4% in October: Crecon
December 8, 2023
- Keytruda Scores No. 1 in Japan Sales Ranking in November: Encise
December 8, 2023
- Daiichi Sankyo, Novartis Settle Patent Infringement Dispute Over Tafinlar
December 7, 2023
- CSL Launches Home Delivery Service for HAE Drug Berinert
December 7, 2023
ページ
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
